Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu

Bioconjugate Chemistry

Volumn 22, Issue 12, 2011, Pages 2444-2452

  Mohsin, Huma ^a   Jia, Fang ^a   Bryan, Jeffrey N ^a   Sivaguru, Geethapriya ^a   Cutler, Cathy S ^a   Ketring, Alan R ^a   Miller, William H ^a   Simón, Jim ^c   Frank, R Keith ^c   Theodore, Louis J ^d   Axworthy, Don B ^d   Jurisson, Silvia S ^a   Lewis, Michael R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Career Counseling and Consultation   (United States)

^d Aletheon Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MAMMALS; MONOCLONAL ANTIBODIES; TOXICITY; TUMORS;

ANIMAL MODEL; FUSION PROTEINS; HUMAN COLON CANCER; NUDE MICE; POST INJECTION; POST TREATMENT; RADIOIMMUNOTHERAPY; SALINE CONTROL; STREPTAVIDIN; THERAPEUTIC EFFICACY;

COENZYMES;

ANTINEOPLASTIC AGENT; HOLMIUM 166; LUTETIUM 177; METHOXY 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CC49 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY HO 166; METHOXY 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CC49 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY LU 177; METHOXY 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CC49 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY PM 149; PROMETHIUM 149; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84555186975     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200258x     Document Type: Article

References (61)

1. Eary, J. F. (1991) Radioimmunotherapy of B-cell lymphoma Ann. Oncol. 2 (Suppl. 2) 187-190
2. Muraro, R., Kuroki, M., Wunderlich, D., Poole, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., Noguchi, P., and Schlom, J. (1988) Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen Cancer Res. 48, 4588-4596
3. Sheer, D. G., Schlom, J., and Cooper, H. L. (1988) Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3 Cancer Res. 48, 6811-6818 (Pubitemid 19012211)
4. Johnston, W. W., Szpak, C. A., Thor, A., and Schlom, J. (1986) Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3 Cancer Res. 46, 6462-6470 (Pubitemid 17221802)
5. Lyubsky, S., Madariaga, J., Lozowski, M., Mishriki, Y., Schuss, A., Chao, S., and Lundy, J. (1988) A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3 Am. J. Clin. Pathol. 89, 160-167 (Pubitemid 18057167)
6. Nuti, M., Yoshio, A., Teramato, Y. A., Mariani-Costantini, R., Horan Hand, P., Colcher, D., and Schlom, J. (1982) A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations Int. J. Cancer 29, 539-545 (Pubitemid 12114628)
7. Ohuchi, N., Thor, A., Nose, M., Fujita, J., Kyogoku, M., and Schlom, J. (1986) Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach Int. J. Cancer 38, 643-650 (Pubitemid 17189121)
8. Stramignoni, D., Bowen, R., Atkinson, B. F., and Schlom, J. (1983) Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas Int. J. Cancer 31, 543-552 (Pubitemid 13058330)
9. Thor, A., Gorstein, F., Ohuchi, N., Szpak, C. A., Johnston, W. W., and Schlom, J. (1986) Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3 J. Natl. Cancer Inst. 76, 995-1003
10. Thor, A., Ohuchi, N., Szpak, C. A., Johnston, W. W., and Schlom, J. (1986) Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3 Cancer Res. 46, 3118-3124 (Pubitemid 16074337)
11. Molinolo, A., Simpson, J. F., Thor, A., and Schlom, J. (1990) Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue Cancer Res. 50, 1291-1298 (Pubitemid 20084025)
12. Colcher, D., Minelli, M. F., Roselli, M., Muraro, R., Simpson-Milenic, D., and Schlom, J. (1988) Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies Cancer Res. 48, 4597-4603
13. Schlom, J., Eggensperger, D., Colcher, D., Molinolo, A., Houchens, D., Miller, L. S., Hinkle, G., and Siler, K. (1992) Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates Cancer Res. 52, 1067-1072
14. Divgi, C. R., Scott, A. M., Dantis, L., Capitelli, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., Kostakoglu, L., Schlom, J., and Larson, S. M. (1995) Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma J. Nucl. Med. 36, 586-592
15. 131I-CC49 in colorectal cancer Cancer 73, 1057-1066 (Pubitemid 24046670)
16. Tempero, M., Leichner, P., Dalrymple, G., Harrison, K., Augustine, S., Schlom, J., Anderson, J., Wisecarver, J., and Colcher, D. (1997) High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial J. Clin. Oncol. 15, 1518-1528 (Pubitemid 27167388)
17. Pavlinkova, G., Booth, B. J. M., Batra, S. K., and Colcher, D. (1999) Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct Clin. Cancer Res. 5, 2613-2619 (Pubitemid 29437349)
18. Volkert, W. A. and Hoffman, T. J. (1999) Therapeutic radiopharmaceuticals Chem. Rev. 99, 2269-2292
19. Barbet, J., Peltier, P., Bardet, S., Vuillez, J. P., Bachelot, I., Denet, S., Olivier, P., Leccia, F., Corcuff, B., Huglo, D., Proye, C., Rouvier, E., Meyer, P., and Chatal, J. F. (1998) Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA - Anti-DTPA-indium bispecific antibody J. Nucl. Med. 39, 1172-1178 (Pubitemid 28326146)
20. Gautherot, E., Le Doussal, J.-M., Bouhou, J., Manetti, C., Martin, M., Rouvier, E., and Barbet, J. (1998) Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens J. Nucl. Med. 39, 1937-1943 (Pubitemid 28518896)
21. Goodwin, D. A., Meares, C. F., McCall, M. J., McTigue, M., and Chaovapong, W. (1988) Pretargeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens J. Nucl. Med. 29, 226-234 (Pubitemid 18056734)
22. 90Y radioimmunotherapy Cancer Res. 54, 5937-5946
23. V6/anti-gallium chelate antibodies J. Nucl. Med. 39, 1769-1776 (Pubitemid 28473528)
24. Kranenborg, M. H. G. C., Boerman, O. C., Griffiths, G. L., Oosterwijk, J. C., de Weijert, M. C. A., McBride, B., Hansen, H. J., Oosterwijk, E., and Corstens, F. H. M. (1998) Two-step targeting of RCC tumors in mice: improved tumor uptake and retention with a bivalent chelate J. Nucl. Med. 39, 78P
25. Le Doussal, J.-M., Chetanneau, A., Gruaz-Guyon, A., Martin, M., Gautherot, E., Lehur, P.-A., Chatal, J.-F., Delaage, M., and Barbet, J. (1993) Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response J. Nucl. Med. 34, 1662-1671 (Pubitemid 23295375)
26. 90Y delivery to mouse tumor xenografts Tumor Targeting 2, 156-157
27. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F.-M., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity Proc. Natl. Acad. Sci. U.S.A. 97, 1802-1807 (Pubitemid 30118523)
28. Cremonesi, M., Ferrari, M., Chinol, M., Stabin, M. G., Grana, C., Prisco, G., Robertson, C., Tosi, G., and Paganelli, G. (1999) Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients Eur. J. Nucl. Med. 26, 110-120 (Pubitemid 29140023)
29. Dosio, F., Magnani, P., Paganelli, G., Samuel, A., Chiesa, G., and Fazio, F. (1993) Three-step tumor pre-targeting in lung cancer immunoscintigraphy J. Nucl. Biol. Med. 37, 228-232 (Pubitemid 24120731)
30. Foulon, C. F., Alston, K. L., and Zalutsky, M. R. (1998) Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy Nucl. Med. Biol. 25, 81-88 (Pubitemid 28032158)
31. Foulon, C. F., Bigner, D. D., and Zalutsky, M. R. (1999) Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications Bioconjugate Chem. 10, 867-876 (Pubitemid 29456376)
32. Kalofonos, H. P., Rusckowski, M., Siebecker, D. A., Sivolapenko, G. B., Snook, D., Lavender, J. P., Epenetos, A. A., and Hnatowich, D. J. (1990) Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication J. Nucl. Med. 31, 1791-1796 (Pubitemid 20374512)
33. Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., Adams, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I. D., and Weiner, L. M. (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer Clin. Cancer Res. 6, 406-414 (Pubitemid 30111457)
34. 64Cu for tumor imaging and therapy J. Nucl. Med. 44, 1284-1292 (Pubitemid 39655189)
35. 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice Nucl. Med. Biol. 31, 213-223 (Pubitemid 38315116)
36. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., Seccamani, E., Siccardi, A. G., and Fazio, F. (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients Cancer Res. 51, 5960-5966
37. Paganelli, G., Orecchia, R., Jereczek-Fossa, B., Grana, C., Cremonesi, M., De Braud, F., Tradati, N., and Chinol, M. (1998) Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy Eur. J. Nucl. Med. 25, 1336-1339 (Pubitemid 28446063)
38. Saga, T., Weinstein, J. N., Jeong, J. M., Heya, T., Lee, J. T., Le, N., Paik, C. H., Sung, C., and Neumann, R. D. (1994) Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin Cancer Res. 54, 2160-2165 (Pubitemid 24138690)
39. TM) for treatment of non-Hodgkins lymphoma (NHL): initial phase I/II study results Cancer Biother. Radiopharm. 15, 15-29 (Pubitemid 30108614)
40. Bos, E. S., Kuijpers, W. H. A., Meesters-Winters, M., Pham, D. T., de Haan, A. S., van Doornmalen, A. M., Kaspersen, F. M., van Boeckel, C. A. A., and Gougeon-Bertrand, F. (1994) In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer Cancer Res. 54, 3479-3486 (Pubitemid 24225970)
41. Kuijpers, W. H. A., Bos, E. S., Kaspersen, F. M., Veeneman, G. H., and van Boeckel, C. A. A. (1993) Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer Bioconjugate Chem. 4, 94-102
42. 99mTc-labeled morpholino, a DNA analog J. Nucl. Med. 43, 384-391 (Pubitemid 34208101)
43. Wang, Y., Chang, F., Zhang, Y., Liu, N., Liu, G., Gupta, S., Rusckowski, M., and Hnatowich, D. J. (2001) Pretargeting with amplification using polymeric peptide nucleic acid Bioconjugate Chem. 12, 807-816 (Pubitemid 32925883)
44. Yao, Z., Zhang, M., Kobayashi, H., Sakahara, H., Nakada, H., Yamashina, I., and Konishi, J. (1995) Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase J. Nucl. Med. 36, 837-841
45. Zhang, M., Sakahara, H., Yao, Z., Saga, T., Nakamoto, Y., Sato, N., Nakada, H., Yamashina, I., and Konishi, J. (1997) Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody Nucl. Med. Biol. 24, 61-64 (Pubitemid 27147913)
46. Sung, C. and van Osdol, W. W. (1995) Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding J. Nucl. Med. 36, 867-876
47. Goodwin, D. A. (1995) Tumor pretargeting: almost the bottom line J. Nucl. Med. 36, 876-879
48. Ngai, W. M., Reilly, R. M., Polihronis, J., and Shpitz, B. (1995) In vitro and in vivo evaluation of streptavidin immunoconjugates of the second generation TAG-72 monoclonal antibody CC49 Nucl. Med. Biol. 22, 77-86
49. Graves, S. S., Dearstyne, E., Lin, Y., Zuo, Y., Sanderson, J., Schultz, J., Pantalias, A., Gray, D., Axworthy, D., Jones, H. M., and Auditore-Hargreaves, K. (2003) Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy Clin. Cancer Res. 9, 3712-3721 (Pubitemid 37169240)
50. Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallett, R., Wilbert, S., and Axworthy, D. (2000) A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy Cancer Res. 60, 6663-6669
51. Buchsbaum, D. J., Khazaeli, M. B., Axworthy, D. B., Schultz, J., Chaudhuri, T. R., Zinn, K. R., Carpenter, M., and LoBuglio, A. F. (2005) Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein Clin. Cancer Res. 11, 8180-8185 (Pubitemid 41698762)
52. 111In-DOTA- biotin in an intraperitoneal tumor model Cancer Biother. Radiopharm. 15, 395
53. 177Lu Bioconjugate Chem. 17, 485-492
54. 177Lu radionuclides Cancer Biother. Radiopharm. 20, 436-449 (Pubitemid 41216108)
55. Hui, T. E., Fisher, D. R., Kuhn, J. A., Williams, L. E., Nourigat, C., Badger, C. C., Beatty, B. G., and Beatty, J. D. (1994) A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates Cancer 73 (Suppl.) 951-957 (Pubitemid 24046655)
56. Briesmeister, J. F., Ed. (2000) MCNP-A General Monte Carlo N-Particle Transport Code, Version 4C, Report LA-13709-M, Los Alamos National Laboratory, Los Alamos, NM.
57. ORNL. ((1995) NUCDECAY: Nuclear decay data for radiation dosimetry calculations for ICRP and MIRD. RSICC DATA LIBRARY DLC-172, Oak Ridge National Laboratories.
58. Bryan, J. N., Jia, F., Mohsin, H., Sivaguru, G., Anderson, C. J., Miller, W. H., Henry, C. J., and Lewis, M. R. (2011) Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy Cancer Biol. Ther. 11, 1001-1007
59. 90Y antibody therapy of colon cancer xenografts in nude mice Cancer Res. 50 (Suppl.) 1008s-1010s (Pubitemid 20054258)
60. 131I-labeled CC49 for therapy in a colon cancer xenograft model Clin. Cancer Res. 5 (Suppl.) 3153s-3159s (Pubitemid 29493909)
61. Forero-Torres, A., Shen, S., Breitz, H., Sims, R. B., Axworthy, D. B., Khazaeli, M. B., Chen, K. H., Percent, I., Besh, S., LoBuglio, A. F., and Meredith, R. F. (2005) Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein Cancer Biother. Radiopharm. 20, 379-390 (Pubitemid 41216102)